"The Once A Day Protease Inhibitor Regimens"
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party)
Roberto Arduino, The University of Texas Health Science Center, Houston
First received: October 18, 2005
Last updated: December 12, 2013
Last Verified: December 2013
History of Changes
Atazanavir (ATV) and fosamprenavir (fAPV) are new protease inhibitors that can be
administered once-a-day and boosted with ritonavir (r). Prior studies have demonstrated that
both are effective in treatment of ARV-naïve HIV-infected people. This study was designed to
demonstrate if a HAART regimen containing ATV/r is not inferior to a HAART regimen containing
fAPV/r, in ARV-naïve patients over a 96-week period.
This is a phase IV, single center, randomized, open label, 2-arm clinical trial in ARV therapy-naïve patients with HIV-1 RNA >1,000 copes/mL and CD4 cell count <350 cells/mm3. Patients will be randomized to receive tenofovir and emtricitabine plus either ATV (300mg qd) and ritonavir (100mg qd) or fAPV (1400mg qd) and ritonavir (200mg qd).
Drug : ritonavir-boosted atazanavir
Drug : ritonavir-boosted fosamprenavir
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||"PIQD: The Once a Day Protease Inhibitor Regimens." Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.|
Further study details as provided by Roberto Arduino, The University of Texas Health Science Center, Houston:
Primary Outcome Measures
- Proportion of Patient With Viral Load Less Than 400 Copies/mL [ Time Frame: 24 weeks ]
- CD4 Cell Count Change From Baseline During Treatment. [ Time Frame: 24 weeks. ]
|Study Start Date:||May 2004|
|Study Completion Date:||March 2010|
|Primary Completion Date:||March 2010 (Final data collection date for primary outcome measure)|
Atazanavir oral once daily
100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Other Name: Reyataz plus Norvir
Fosamprenavir oral once daily
100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Other Name: Lexiva plus Norvir
Over the past decade, there have been significant advances toward fighting the progression of HIV disease. Current treatment strategies consist of utilization of potent combination antiretroviral therapy to suppress HIV replication below detectable limits limiting the potential for the emergence of resistant viruses, boosting CD4 cell counts and thereby delaying disease progression. Treatment of HIV-1 infection with Highly Active Antiretroviral Therapy (HAART) regimens containing a protease inhibitor (PI) and two nucleoside reverse transcriptase inhibitor (NRTIs) has been shown to prolong survival and decrease disease progression. Despite these potent antiretroviral agents, current available therapies continue to fail in some patients. Poor adherence to complex treatment regimens remains a significant cause of suboptimal viral suppression leading to emerge of resistant virus. Atazanavir and fosamprenavir were recently FDA approved protease inhibitors. The efficacy and safety profile of these two drugs have been established in clinical trials enrolling antiretroviral therapy naïve and protease inhibitor experienced patients. Atazanavir and fosamprenavir are the only protease inhibitors approved for a once a day regimen and this may set a new standard for treatment of antiretroviral therapy naïve HIV infected patients. Adherence to the medicines, a key component of treatment success, could be significantly improved by using these once daily regimens. However, no head-to-head trials comparing the safety and efficacy of fosamprenavir and atazanavir have been published. This prospective, randomized, open label 2-arm study will compare these two protease inhibitors for therapy of antiretroviral treatment-naïve HIV-infected patients. Patients who are successfully screened for eligibility will be randomized to receive tenofovir and emtricitabine plus either atazanavir (300mg qd) and ritonavir (100mg qd) or fosamprenavir (1400mg qd) and ritonavir (200mg qd). Participants will undergo assessment on day 1 and attend study visits at weeks 6, 12 and every 3 months until the completion of the study on week 96. "Antiretroviral Medication Self-Report" and "3-Day HIV Medication Self-Report" questionnaires will be applied at weeks 6, 12 and every 3 month, thereafter, until week 96. "Changes in Body Appearance" questionnaire will be applied at baseline and weeks 24, 48, 72, and 96.Eligibility
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 18 years of age or older.
- Patient agrees to participate in the study by giving written informed consent.
- Documentation of HIV infection.
- No prior treatment with any anti-retroviral agent.
- CD4 cell count < 350 cells x mm3 or with an AIDS defining condition.
- Viral load > 1,000 copies/mL
- Less than 18 years old.
- Current pregnancy or breastfeeding.
- Any previous antiretroviral regimen.
- Severe hepatic impairment that precludes the use of either study drug. This will be defined as any laboratory value of Grade 3 or 4 on the ACTG scale.
- Use of any contra-indicated medication as defined in the package insert for each drug.
- Any condition that, in the judgment of the investigator, precludes successful
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00242216
Locations Show More
|United States, Texas|
|Thomas Street Health Center|
|Houston, Texas, United States, 77009|
Sponsors and CollaboratorsThe University of Texas Health Science Center, Houston
|Principal Investigator:||Roberto C Arduino, MD||The University of Texas Health Science Center, Houston|
|Responsible Party:||Roberto Arduino, Professor - Internal Medicine, The University of Texas Health Science Center, Houston|
|ClinicalTrials.gov Identifier:||NCT00242216 History of Changes|
|Other Study ID Numbers:||HSC-MS-03-315|
|Study First Received:||October 18, 2005|
|Last Updated:||December 12, 2013|
Keywords provided by Roberto Arduino, The University of Texas Health Science Center, Houston:HIV-1 infected people
ARV Treatment Naive
Additional relevant MeSH terms:
HIV Protease Inhibitors
ClinicalTrials.gov processed this data on October 15, 2019
This information is provided by ClinicalTrials.gov.